drugset / Trial / NCT02312882

Tofacitinib for the Treatment of Alopecia Areata and Its Variants

NCT02312882

Completed 40 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Timeline

Start
2014-12
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 5 mg Oral